global messaging alerts

Expert Content

ApiJect experts share knowledge and know-how to deliver innovative solutions customized to achieve our customer's goals and objectives.

Data Sheets

  • April 7, 2022

    Global Manufacturing Supply Chain Resiliency

    We have created a compact and flexible supply chain that can be almost entirely domestic in major markets. This is because we rely on two robust manufacturing technologies to make our platform: Blow-Fill-Seal (BFS) aseptic filling and plastic injection molding.

  • March 9, 2022

    BFS Temperature Management

    Our BFS manufacturing experts employ a variety of techniques to consistently manage the drug product’s temperature throughout the fill-finish process.

  • March 9, 2022


    Our experts marry the efficiency and flexibility of BFS with attachable plastic components to create drug delivery systems. This approach has the potential to enable scalable and efficient manufacturing of single-dose prefilled syringe which can typically only be found in multi-dose presentations.

  • March 9, 2022

    Partnering: Pharmaceutical Companies

    We help pharma companies fill-finish sterile liquids by working together to create BFS based, prefilled drug delivery systems, and then assist in the fill-finish process. The result is a prefilled drug delivery system that can be flexibly manufactured at various facilities that use BFS.

  • March 9, 2022

    ApiJect Company Profile

    ApiJect is a medical technology company that seeks to improve how companies fill-finish injectable medicines. We do this by working with pharma partners to design rapidly-scalable drug delivery systems, and assist in manufacturing those devices at their facilities or a trusted CMO/CDMO.

Industry Insights

  • June 29, 2022

    How Blow-Fill-Seal Delivers Operational Efficiencies and Aseptic Fill-Finish
    with Joe Wojcik, BFS Engineer

    Pharma expert, Joe Wojcik, discusses the technical factors and requirements that make BFS an “advanced aseptic process” for fill-finish, and why BFS has relatively low capital requirements

  • December 8, 2021

    What Have Been the Biggest Surprises with COVID-19?
    with Ed Kelley, PhD, Chief Global Health Officer

    The pandemic’s effects have been far more wide-reaching than many health officials expected, but COVID has also accelerated some positive trends.

  • November 9, 2021

    Advances in Sterile Liquids Packaging and Form Factors
    with Jon Burgess, Packaging Engineer

    Discussion  on packaging factors that have led to wider acceptance of Blow-Fill-Seal technology in the pharmaceutical industry.

  • November 2, 2021

    Strengths of Diversity in Pharma
    with Amy Stewart, Chief People Officer

    Companies are realizing that a strong commitment to DEI and ESG attracts employees. Word of mouth is very powerful. Companies want to do business with partners that are inclusive with positive values and environmental initiatives.

  • July 30, 2021

    The Surprising Strengths of Blow-Fill-Seal
    with Philip Leslie, Acting Head of Manufacturing

    Why does the FDA calls BFS an “advanced aseptic process”? How does BFS combine high-speed, economically efficient production with notable manufacturing flexibility? Respected industry veteran Philip Leslie explains “the basics of BFS.”

  • May 11, 2021

    BFS Covers Injectables and Vaccines, Too
    with Ray Sell, Vice President, Business Development

    BFS drug delivery systems go far beyond ophthalmic and oral solutions; BFS is also used to fill-finish injectables and vaccines.

  • March 3, 2021

    The Heat Factor: Part 1 & 2:Why it Matters in Blow-Fill-Seal
    with Jeff Price, Consulting Principal BFS Engineer

    At ApiJect, our engineers have taken BFS filling enhancements even further by developing proprietary temperature control management methods that can potentially enable many temperature sensitive biologics and vaccines that are not possible on standard BFS lines.

Published Articles

  • August 25, 2021

    Single-Dose Drug Delivery Fill-Finish Facility that is Scalable, Flexible, and able to Deliver up to 45M Units Per Month Delivered within an Accelerated Timeline of Fewer Than 7 Months
    Part 3 of Pharmaceutical Technology Post-Webinar Series

    ApiJect committed to creating emergency temporary fill-finish capacity for up to 45M doses a month of a candidate COVID-19 vaccine on BFS lines by the end of 2020. All of these BFS-packaged doses could then be used, if necessary, in ApiJect Prefilled Injectors for scalable, single-dose delivery.

  • August 24, 2021

    Solving Drug Challenges with Innovation, BFS, and a Technology Platform to Create Drug
    Delivery Systems
    Part 2 of Pharmaceutical Technology Post-Webinar Series

    Learn how ApiJect built its Technology Platform around BFS to create innovative drug delivery systems for the prefilled syringe market and other sterile liquid pharmaceutical delivery formats.

  • August 23, 2021

    BFS and Prefilled Syringes: A Solution for Complex Formulations
    Part 1 of Pharmaceutical Technology Post-Webinar Series

    Many countries, including the US, lack the necessary surge capacity to reliably fill-finish and deliver billions of incremental doses of injectable drugs and vaccines during bio-emergencies.

  • May 9, 2021

    Special Feature: PFS & Parenteral Manufacturing: How COVID-19 Changed the Market
    Drug Development & Delivery, Issue: May 2021

    Worldwide, the parenteral market is seeing greater emphasis on patient safety. This is driving a strong trend to­ward unit-dose formats, including Blow-Fill-Seal pre­filled syringe, which are now the fastest-growing format for injectables.


  • June 15, 2022

    Chats with Chaudhrey: Dawn Carlson at BIO 2022

    Rizwan chats with Dawn, Vice President of Pharma Development, to learn more about the ApiJect Platform which enables pharma and biotech companies to design scalable prefilled injectors and help efficiently fill-finish them with their injectable drug product.

  • March 17, 2022

    Chats with Chaudhrey: “DCAT Week 2022”, Ray Sell

    Rizwan caught up with Ray for a quick preview of what ApiJect would be taking to attendees about at DCAT Week which runs March 21st-24th March, New York City.

  • January 25, 2022

    Chats with Chaudhrey: “Fareva Licensing Agreement”. Jay Walker

    Rizwan chats with Jay, Executive Chairman at ApiJect, to learn more about ApiJect’s recent licensing agreement signed with Fareva to create a France-based 500M unit annual capacity for single-dose pre-filled vaccine injections.

  • October 19, 2021

    Live with Chaudhrey: Ray Sell at INTERPHEX 2021

    As Rizwan couldn’t make INTERPHEX 2021, he caught up with Ray Sell  at ApiJect’s booth via Zoom from while he attended ELRIG UK Drug Discovery 2021 in Liverpool.

  • October 9, 2021

    Chats with Chaudhrey: “INTERPHEX 2021 Preview”, Josh Myers

    Rizwan chats with Josh last week to learn what ApiJect was doing at INTERPHEX 2021. Learn about our Technology Platform that brings together aseptic BFS with connectable components to create high-quality prefilled drug delivery systems

  • August 18, 2021

    Chats with Chaudhrey: “Syringe Reuse”, Edward Kelley, PhD

    Interesting chat with Edward Kelley, Chief Health Officer, ApiJect, and formerly the Head, Strategic Programs, at the World Health Organization about syringe reuse, the causes, impact, and how to help overcome it.

  • June 22, 2021

    Chats with Chaudhrey: “Blow-Fill-Seal”, Philip Leslie

    Rizwan chats with Philip to learn more about the advantages and which types of products can be made using BFS.

  • June 22, 2021

    Chats with Chaudhrey: “How to Progress your Products in BFS”, Philip Leslie

    Rizwans chats with Philip to learn more about the advantages and which types of products can be made using BFS.


  • April 8, 2022

    Join the ApiJect team! We’re always looking for passionate teammates.

    We envision a world where every country can safely, locally, and cost-effectively package and deliver all of the essential injectable medicines and vaccines its citizens need to live long, healthy lives.

  • March 9, 2022

    ApiJect Prefilled Injector

    The Prefilled ApiJect Injector* is a delivery system designed to bring together the benefits of prefilled syringes with the manufacturing efficiency of multi-dose presentations. Watch the Video by clicking below.

  • March 9, 2022

    We are ApiJect
    We are a team of passionate and dedicated people. Our mission is to make injectable medicines and vaccines safe and accessible to everyone. Click the button below to watch the video.

  • June 9, 2021

    ApiJect Prefilled Injector Assembly
    The ApiJect Prefilled Injector brings together an aseptically-filled Blow-Fill-Seal (BFS) container and a pen needle-style Needle Hub* to reliably deliver injectable vaccines and medicines. Click the button below to view the video.

  • March 9, 2021

    BFS Manufacturing Line
    What makes BFS truly special is its combination of reliable aseptic filling with its speed and efficiency of production for any size output. In fact, due to its enclosed process and reliability, the industry considers BFS to be an advanced aseptic process. To view the video, click the button below.


  • December 8, 2021

    Fierce Pharma: “Next Supply Chain Challenge: Syringes”

    An estimated 14 to 19 billion incremental injections will be required by year-end 2022 to vaccinate the world’s population against COVID-19 while supplying related boosters and adjuvants. In response, the industry is shifting billions of syringes from routine vaccinations and therapeutics to COVID, increasing existing capacity, and building new manufacturing sites for syringes. Yet COVID’s supply chain is still expected to fall short. What is the source of this looming shortage? Is “syringe nationalism” causing export embargoes? How is the industry responding? Is it a supply chain problem?

    In this webinar, three experts in pharma and global health discuss potential solutions including,

    • Onshoring of production
    • Increasing capacity in existing plants
    • Investing in new facilities
    • Need for Government funding of long-term supply chain infrastructure
    • Resources and technical know-how required for production
    • Need for trained local personnel to put “shots in arms”


    • Ed Kelley, PhD, Chief Global Health Officer, ApiJect
    • Omair Ahmed, Chief Strategy Officer, Nexus Pharmaceuticals
  • October 15, 2021

    INTERPHEX Live 2021: “Creating a Sustainable Public Health Supply Chain”

    Industry experts share insights on how stakeholders can maintain a robust, resilient supply chain essential to global health and vaccine security, with an accelerated response time to meet the needs of current and future pandemics. The building blocks for this supply chain resiliency include tech transfer, designing for right-size capacity, improving operational efficiencies, implementing state-of-the-art technologies, and establishing regulatory and quality systems.


    •  Ed Kelley, PhD, former Director of Integrated Health Services for WHO and Chief Global Health Officer for ApiJect
    • Rob Roy, PE, Director of Aseptic Technology at IPS-Integrated Project Services
    • Paul Fisher, Director of Process Architecture at IPS-Integrated Project Services
    • Jim Fries, Chief Executive Officer, RX-360
  • October 15, 2021

    INTERPHEX Live 2021 Session: “Pros and Cons of Global Fill-Finish”

    Responding to the COVID-19 pandemic, governments and public health agencies worldwide are developing quality vaccine programs, including local fill-finish capacity, to support global immunization. Yet even before COVID, countries were already facing increased vaccine demand due to population growth. The panel will discuss key challenges and opportunities as governments and pharmaceutical manufacturers seek to establish fill-finish facilities around the world to enable access to greater and more diversified vaccine manufacturing while improving preparedness to respond to future pandemics.


    • Ed Kelley, PhD, former Director of Integrated Health Services for WHO; Chief Global Health Officer,  ApiJect
    • Jason Collins, AIA, Director of Process Architecture, IPS-Integrated Project Services
    • Omair Ahmed, Chief Strategy Officer, Nexus Pharmaceuticals
  • August 11, 2022

    Episode 6 – “Current State and Trends Impacting Fill-Finish from Formulation through Commercialization”


    • Guest: Parrish Galliher, Independent Bioprocess Consultant
    • Hosted by: Rizwan Chaudhrey
  • June 23, 2022

    Episode 5 – “Temperature Sensitive Biologics and Blow-Fill-Seal”


    • Guest: Philip Leslie, Acting Head of Manufacturing, ApiJect
    • Hosted by: Rizwan Chaudhrey
  • June 15, 2022

    Episode 4 – “Evolving Trends in Aseptic Processing”


    • Guest: Len Pauzer, President, Pauzer Consulting
    • Hosted by: Rizwan Chaudhrey
  • April 14, 2022

    Episode 3 – “Global Supply Chain Management and Capacity Planning”


    • Guest: Omair Ahmed, Chief Strategy Officer, Nexus Pharmaceuticals
    • Hosted by: Rizwan Chaudhrey
  • March 28, 2022

    Episode 2: “The Past, Present, and Future of Advanced Aseptic Facility Design”


    • Guests: Sterling Kline, RA, Vice President, Design and Jason Collins, AIA, Director of Process Architecture, IPS-Integrated Project Services
    • Hosted by: Rizwan Chaudhrey

  • February 28, 2022

    Episode 1: “Current Trends in Isolation Technology and Vaccine Production”


    • Guest: Les Edwards, Vice President of Technology and Business Development, SKAN US
    • Host: Rizwan Chaudhrey

The ApiJect Story

  • June 9, 2021

    The ApiJect Story
    It turns out that Marc’s solution to the syringe safety problem has the potential to greatly improve how pharma companies fill, finish, and deliver their liquid medicines and vaccines across the board. Read more about Marc’s amazing journey by clicking the button below.

Project Profiles

  • April 14, 2022

    Project Profile: Technology Development Center

    The ApiJect Center is focused on helping pharmaceutical companies prepare their drug product for high-speed, high-volume production in a new type of scalable prefilled syringe that is made largely using the Blow-Fill-Seal aseptic process. The ApiJect Center directly supports the future installation of large-scale commercial manufacturing for rapid deployment of critical medications.

  • December 9, 2021

    Project Profile: Fareva

    Increasing Vaccine Fill-Finish Capacity in France: 500M Unit Annual Capacity for Single-Dose Prefilled Vaccine Injectables

  • July 8, 2021

    Project Profile: The RiteDose Corporation

    In 2020, as part of the U.S. Government’s COVID-19 response, ApiJect™ entered into a long-term strategic partnership with The Ritedose Corporation (“TRC”). Together, they were able to make operational 45 million units per month of Blow-Fill-Seal fill-finish capacity for America’s COVID-19 response within 7 months out of TRC’s facility in Columbia South Carolina.

Intro to BFS

  • April 3, 2022

    Chapter 35: How to Get Started with BFS

  • April 1, 2022

    Chapter 32: Foil Wrap

  • March 31, 2022

    Chapter 31: Particulate Inspection

  • March 30, 2022

    Chapter 30: Leak Detection

  • March 29, 2022

    Chapter 29: Punching, Engraving, and Separating

  • March 28, 2022

    Chapter 28: BFS Machines and Support Systems

  • March 27, 2022

    Chapter 27: Areas of a BFS Line

  • March 26, 2022

    Chapter 26: BFS Molds

  • March 25, 2022

    Chapter 25: Manufacturing Efficiencies

  • March 24, 2022

    Chapter 24: CapEx and Fixed Costs

  • March 23, 2022

    Chapter 23: Equipment

  • March 22, 2022

    Chapter 22: Space and Utilities

  • March 21, 2022

    Chapter 21: Filling Suite Installation

  • March 20, 2022

    Chapter 20: Sensitivity

  • March 19, 2022

    Chapter 19: Comparability and Feasibility Testing

  • March 18, 2022

    Chapter 18: Cost Advantage

  • March 17, 2022

    Chapter 17: Flexible Scaling

  • March 16, 2022

    Chapter 16: Compact Supply Chain

  • March 15, 2022

    Chapter 15: Breakage Resistant

  • March 14, 2022

    Chapter 14: Transportation

  • March 13, 2022

    Chapter 13: High Productivity

  • March 11, 2022

    Chapter 11: Manufacturing Footprint

  • March 10, 2022

    Chapter 10: Cost Efficiency

  • March 9, 2022

    Chapter 9: Sterility Assurance

  • March 8, 2022

    Chapter 8: Low Particulates

  • March 7, 2022

    Chapter 7: Reliable Aseptic Filling

  • March 6, 2022

    Chapter 6: Advantages of BFS

  • March 4, 2022

    Chapter 4: Types of BFS Machines

  • March 3, 2022

    Chapter 3: How BFS Works

  • March 2, 2022

    Chapter 2: Blow-Fill-Seal in Pharma

  • March 1, 2022

    Chapter 1: What is BFS?


  • August 5, 2022

    Overview of BFS Manufacturing & Secondary Packaging Line

  • August 5, 2022

    ApiJect Platform Uses Efficient BFS Manufacturing Processes

  • August 5, 2022

    Blow-Fill-Seal Creates and Fills a Container in a Continuous Process

  • August 5, 2022

    Prefilled ApiJect Injector*—0.5mL Delivery

  • August 5, 2022

    Elements of the Prefilled ApiJect Injector*

  • August 5, 2022

    Prefilled ApiJect Injector*-0.5mL Delivery

random footer image
Social media & sharing icons powered by UltimatelySocial